Severe COVID-19 caused by persistent SARS-CoV-2 infection successfully treated with dual direct acting antivirals [PDF]
, 2022 We report the use of combination therapy with remdesivir and nirmatrelvir/ritonavir (Paxlovid) in successfully treating severe, chronic COVID-19 caused by persistent SARS-CoV-2 infection over 4 months.
Snell, Luke Blagdon +17 more
core
Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
Infection and Drug Resistance, 2023 Cheng-Yi Hu,1 Wen-Shuai Cui,1 Yi Lei,1 Yu-Wen Tang,1 Yan-Yan Zhang,1 Qi-Min Su,1 Fang Peng,2 Yun-Fei Zeng,1 Jia-Lin Song,1 Cheng-Na Luo,1 Yan Zhou,1 Xin-Yan Li,1 Zhu-Xiang Zhao1 1Department of Infectious Diseases, Guangzhou First People’s Hospital ...
Hu CY +12 more
doaj
EClinicalMedicine, 2023 Summary: Background: Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited.
Eric Yuk Fai Wan +10 more
doaj +1 more source
Alkyne derivatives of SARS-CoV-2 main protease inhibitors including nirmatrelvir inhibit by reacting covalently with the nucleophilic cysteine [PDF]
, 2023 Nirmatrelvir (PF-07321332) is a nitrile-bearing small-molecule inhibitor that, in combination with ritonavir, is used to treat infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Brewitz, Lennart +15 more
core +2 more sources
A Streamlined High Performance Liquid Chromatography with Tandem Mass Spectrometry Based Workflow for Rapid Screening of Cellular Accumulation of Small Molecules. [PDF]
ChemMedChemThis study uses six small‐molecule inhibitors to evaluate optimal cellular accumulation assay conditions in a 96‐well format with high performance liquid chromatography with tandem mass spectrometry detection. The obtained medium to high‐throughput workflow is suitable for reliably identifying cellular accumulation, valuable for preclinical selection ...
Metzen A, Rox K.
europepmc +2 more sources
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life [PDF]
, 2023 Background. Several drugs which are easy to administer in outpatient settings have been authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to prevent hospital admission and death, complementing COVID-19 vaccines.
Francesca Larese Filon +4 more
core +1 more source
Annals of Internal Medicine: Clinical Cases, 2023 Since the onset of the SARS-CoV-2 (COVID-19) pandemic, significant effort has been devoted toward developing therapeutics that decrease the morbidity and mortality of COVID-19 infection.
Meaghan Coyne, Myint Aye
doaj +1 more source
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in patients at high risk [PDF]
, 2023 Background Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable. Methods The impact of each drug was determined via comparisons
Antoniadou, Anastasia +18 more
core +1 more source
Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents [PDF]
, 2022 BACKGROUND: The efficacy on the Omicron variant of the approved early- coronavirus disease 2019 (COVID-19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo antiviral activity are ...
Alessandra, Vergori +24 more
core +2 more sources
Antivirals for the treatment of mild and moderate COVID-19 in South Africa [PDF]
, 2023 While the majority of COVID‐19 cases in South Africa (SA) are mild, patients with severe COVID‐19 requiring hospitalisation present with significant morbidity and mortality and place a substantial burden on healthcare services.
Gengiah, T N +3 more
core +2 more sources